Roche Applied Science has revealed that the Genome Sequencer FLX system has helped uncover a genetic variation linking type 1 diabetes with enterovirus infection.
A study by Nejentsev et al published online in 'Science' reports that researchers have discovered a group of rare variants in a disease-associated gene that appear to lower the risk of developing type 1 diabetes (T1D).
The study, conducted by scientists at the Wellcome Trust/JDRF Diabetes and Inflammation Laboratory at the University of Cambridge, used deep sequencing with the Genome Sequencer FLX system from 454 Life Sciences to re-sequence 10 candidate genes including those previously identified by genome-wide associated studies (GWAS) of T1D.
The study presents an insight into the genetic basis of T1D, a common autoimmune disorder that results in the destruction of insulin-producing pancreatic cells.
Also, the study marks one of the first of its kind in discovering a number of protective T1D alleles directly from the results of a previously conducted GWAS.
The findings and scientific method will ultimately provide the knowledge to develop better strategies to detect, treat and prevent T1D and other genetic-based diseases in the future.
T1D is a highly complex, multifactoral disease, meaning that more than one genetic factor, combined with environmental conditions, participates in causation of the condition.
To date, GWAS have identified 15 loci linked to T1D.
While GWAS are widely used to map genomic regions contributing to common human diseases, they often do not identify the precise causative genes and sequence variants which are essential to clinical applications.
To further elucidate these T1D loci, the researchers in the study selected 10 genes for ultra-deep sequencing from the DNA of 480 T1D patients and 480 healthy controls from Great Britain.
From the results they identified 179 rare single-nucleotide polymorphisms (SNPs) and then tested the SNPs' association with the disease by comparing allele frequency in the DNA of more than 30,000 T1D patients, controls and family members.
The final results found four rare SNPs in the IFIH1 gene with strong statistical evidence of association with the disease.
Surprisingly, the results suggest that the rare variants have strong protective effects on T1D risk, meaning that rare alleles of all associated IFIH1 polymorphisms consistently reduce the risk of T1D while IFIH1 alleles carried by the majority of the population predispose to the disease.
Dr John Todd, senior author of the study, said: 'These results pinpoint the IFIH1-MDA5 gene as being causal and actively participating in T1D development, and indicate a route to identifying more genes specifically acting in the disease, from currently a large list of possible candidate genes.
'While these results only account a very small piece of the whole picture, it is an important principal finding.' Interestingly, the researchers found that the protective effects of the rare variants make sense in light of the biological role of the IFIH1 protein.
The protein, also known as MDA5, recognises RNA of picornaviruses and mediates immune activation within the body.
Infection with enteroviruses such as coxsackie, polioviruses and echoviruses, all members of the picornavirus family, are more common among newly diagnosed T1D and pre-diabetic patients than in the general population.
Although details of the underlying mechanism for the IFIH1 gene's contribution to disease state would still have to be studied, these variants are predicted to alter transcript splicing or result in truncation of the gene product.
This suggests that the variants, which would be expected to reduce function of the IFIH1 protein, decrease the risk of T1D while normal gene function is positively associated with disease.
Dr Sergey Nejentsev, the first author of the study, said: 'Finding several new rare disease variants with clear biological functions was crucial.
'Not only has this proved that IFIH1 is involved in T1D, it also gave us clues to understand the mechanism.' The use of deep 454 Sequencing of amplicons, which enables highly sensitive detection of rare mutations, to even as low as one per cent of the allele population, has applications to similar studies in a wide variety of complex diseases.
Michael Egholm, chief technology officer at 454 Life Sciences, said: 'We are pleased to see 454 Sequencing being used for this type of translational research.
'The method outlined in this study pushes the information obtained in GWAS to the next level by identifying actual causative and protective mutations which will potentially serve as targets for detecting, treating and preventing type 1 diabetes and other diseases in the future.'
